Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 7/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.41 |
| ▸ | CASR | P41180 | 3/20 | 0.40 |
| ▸ | AURKA | O14965 | 3/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 2/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3892410 | 0.97 | IRAK4 (0.43) | JAK3IRAK4CASRAURKARPS6KB1 | |
| SCHEMBL3881918 | 0.87 | CASR (0.38) | JAK3IRAK4CASRSRCEGFR | |
| SCHEMBL3881367 | 0.87 | IRAK4 (0.43) | JAK3IRAK4AURKARPS6KB1PDE4B | |
| SCHEMBL3883320 | 0.81 | IRAK4 (0.37) | JAK3IRAK4PDE4BEGFR | |
| SCHEMBL3886266 | 0.80 | IRAK4 (0.37) | JAK3IRAK4EGFR | |
| SCHEMBL3880153 | 0.77 | EGFR (0.39) | PDE4BSRCEGFR | |
| SCHEMBL14452551 | 0.77 | IRAK4 (0.44) | JAK3IRAK4CASRAURKARPS6KB1 | |
| SCHEMBL3996368 | 0.77 | EGFR (0.35) | JAK3IRAK4AURKARPS6KB1EGFR | |
| SCHEMBL3883496 | 0.75 | EGFR (0.34) | JAK3IRAK4EGFRROCK2ROCK1 | |
| SCHEMBL3889429 | 0.75 | EGFR (0.34) | JAK3IRAK4EGFRROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771443-B1 | QUINOLINE THIAZOLINONES WITH CDK-1 ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-7250515-B2 | Thiazolinone 3,4-disubstituted quinolines | HOFFMAN-LA ROCHE INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CHEN LI | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004046-A1 | Thiazolinone 3,4-disubstituted quinolines | CDK1, CDK17, CDK14 | JAK3 548/4885IRAK4 2540/4885CASR 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.